White Pine Capital LLC Has $510,000 Position in Pfizer Inc. (NYSE:PFE)

White Pine Capital LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 47.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,234 shares of the biopharmaceutical company’s stock after acquiring an additional 6,196 shares during the period. White Pine Capital LLC’s holdings in Pfizer were worth $510,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 11.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock valued at $3,766,366,000 after purchasing an additional 12,864,343 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after buying an additional 6,977,587 shares in the last quarter. International Assets Investment Management LLC bought a new position in Pfizer in the third quarter valued at about $146,481,000. Van ECK Associates Corp raised its stake in Pfizer by 28.5% during the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock worth $564,739,000 after acquiring an additional 4,726,549 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Pfizer by 164.2% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,316,405 shares of the biopharmaceutical company’s stock worth $211,737,000 after acquiring an additional 4,546,809 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

PFE stock opened at $25.64 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company’s fifty day simple moving average is $26.28 and its 200 day simple moving average is $27.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The firm has a market cap of $145.28 billion, a price-to-earnings ratio of 18.18, a PEG ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 earnings per share. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.71%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is presently 121.99%.

Analyst Ratings Changes

Several brokerages recently issued reports on PFE. UBS Group decreased their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Guggenheim reaffirmed a “buy” rating and issued a $33.00 target price on shares of Pfizer in a report on Monday. Finally, StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.